-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Osteoporosis is a common disease characterized by reduced bone mass and microarchitecture in patients, leading to an increased risk of osteoporotic fractur.
Osteoporosis is a common disease characterized by reduced bone mass and microarchitecture in patients, leading to an increased risk of osteoporotic fractur.
Infect
This was a population-based, propensity-matched retrospective cohort study including patients ≥50 years of age who had been treated with PPIs for more than 180 da.
In the Korea National Health Insurance Agency (NHIS)-CDM database, researchers found that long-term PPI users had a greater risk of osteoporosis (PPI vs non-PPI group, 242/1000 person-years vs 129/1000 person-years; HR, 62; 95% CI, 22–15; P=00
The results of this study confirmed that long-term PPI was significantly associated with osteoporosis, but the results for hip fracture were inconsiste.
The results of this study confirmed that long-term PPI was significantly associated with osteoporosis, but the results for hip fracture were inconsiste.
Original source:
Da Hee Pa.
Da Hee Pa.
Et .
Long-term proton pump inhibitor use and risk of osteoporosis and hip fractures: a nationwide population-based and multicenter cohort study using a common data mod.
Journal of Gastroenterology and Hepatolo.
202 Long-term proton pump inhibitor use and risk of osteoporosis and hip fractures: a nationwide population-based and multicenter cohort study using a common data mod.
Leave acomment here
